SAN DIEGO, July  13, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Treace Medical Concepts, Inc. (NASDAQ:TMCI) against certain of its

TMCI

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI)

Johnson Fistel Investigates Treace TMCI for Fiduciary Breach Allegations

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, July  13, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Treace Medical Concepts, Inc. (NASDAQ:TMCI) against certain of its</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Johnson Fistel is investigating Treace Medical Concepts (TMCI) for potential fiduciary-duty breaches. The release highlights possible governance reforms and shareholder remedies for long-term holders, tied to allegations about Lapiplasty demand and revenue declines. The catalyst is ongoing legal scrutiny, with limited immediate cash impact and potential sentiment risk if new facts emerge.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Johnson Fistel probes Treace TMCI for fiduciary breaches; potential governance reforms.</li><li>Holders since before May 8, 2023 may pursue reforms and incentive awards.</li><li>Complaint alleges competition hit Lapiplasty demand and Treace revenue decline.</li><li>No-cost participation; law firm highlights past settlements and results.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Treace Medical Concepts, Inc. (TMCI)</strong>: Subject of fiduciary-duty investigation; governance reforms and potential settlement risk.</li><li><strong>Johnson Fistel, PLLP</strong>: Leading the investigation; may influence investor sentiment though no direct cash impact stated.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. The piece centers on a fiduciary-duty investigation and potential securities actions, affecting Treace&#039;s governance narrative and investor perception rather than immediate financial metrics.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Legal investigations can trigger short-term TMCI price volatility.</li><li>No-cost participation signals limited immediate cash impact but elevated perception risk.</li><li>Allegations on Lapiplasty demand may affect sentiment if substantiated.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date of release: July 13, 2026.</li><li>Holders prior to May 8, 2023 may have standing to seek reforms.</li><li>Allegations include competition impacting Lapiplasty demand and revenue decline.</li><li>Participation in the investigation is at no cost to shareholders.</li><li>Previously filed securities class action alleges misstatements and omissions.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral to slightly negative near term; TMCI could drift on legal news unless material developments emerge.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, July  13, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Treace Medical Concepts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TMCI">TMCI</a>) against certain of its officers and directors for alleged breaches of fiduciary duty.</p>  <p>Shareholders who have held Treace shares continuously since prior to May 8, 2023, may have standing to seek corporate governance reforms, the return of funds back to the company, and a court-approved incentive award, all at no cost to them.</p>  <p><strong>What Should Treace Shareholders Do?</strong><br></br>If you have held Treace shares continuously since prior to May 8, 2023, you may have standing to seek corporate governance reforms at Treace, including improvements to internal controls, transparency, and executive oversight.</p>  <p>To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=mR5iZUQJzimSLolAhWdOd862doCW4EmDjLGgTVjHc-pc0NwmHJ5IlbAurUKJHkh2JvZzpLmtV3OSdPJYrtg-ZbjHdhfaUuY5i3Qf0Wob27Jf-zl76kQxWRaRzEzb3IprBAGIgw_jkEQ7zUfVYrCSLNIZCyoYtCEpHHfbwjmKeo_qKR3sQ-dm6FY9ZyI0QEDTmMAQ9BOsWKjV_PTXBpdXv9uH8tVy-5lDfvL7mjUp7iw=" rel="nofollow" target="_blank">https://www.johnsonfistel.com/investigations/treace-medical-concepts-inc/</a> or contact Johnson Fistel, PLLP at <a href="https://www.globenewswire.com/Tracker?data=4Ish30c-vBdp8Ilef0RMhg2vkuwrcxTADdU4rgvGsMX7oMctODr72_2sSyceaVL-T-b8gZe_SjIXRHWSDwlSEjh28fP6hTTnjk0stqHB2nM=" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a> or (619) 814-4471.</p>  <p>There is no cost or obligation to you.</p>  <p><strong>What Is Johnson Fistel Investigating?</strong><br></br>A previously filed securities class action complaint alleges that Treace and certain of its executives made materially false and misleading statements, and/or failed to disclose material adverse facts, concerning the Company&#39;s business, operations, and prospects.</p>  <p>The filed complaint alleges that defendants made false statements and/or concealed that: (1) competition impacted the demand for and utilization of its primary product, the 3D bunion correction system, the &#34;Lapiplasty&#34;; (2) as a result, Treace Medical&#39;s revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function); and (3) defendants&#39; positive statements about the Company&#39;s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.</p>  <p><strong>About Johnson Fistel, PLLP &#x7C; Top Law Firm, Securities Fraud, Investor Rights:</strong><br></br>Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on U.S. exchanges. For more information about the firm and how we may be able to help you recover your losses, please visit <a href="https://www.globenewswire.com/Tracker?data=5PY9SBCNuNBLx15NGKcpklot7ScOtOJeYDdQMwDFcAy-3AMD4qpN4pB59nDEReQgpulmZ_RBPW0-BKDR4bD54voMeSzvJK8bPXX9DRQvQrc=" rel="nofollow" target="_blank">www.johnsonfistel.com</a>.</p>  <p><strong>Achievements:</strong></p>  <p>In 2024, Johnson Fistel was ranked in the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. The firm has recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel, marking the eighth time it has been recognized among the top U.S. plaintiffs&#39; securities law firms.</p>  <p>Attorney Advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.</p>  <p><strong>Contact:</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800<br></br>San Diego, CA 92101<br></br>James Baker, Investor Relations or Frank J. Johnson, Esq.<br></br>(619) 814-4471<br></br><a href="https://www.globenewswire.com/Tracker?data=4Ish30c-vBdp8Ilef0RMhg2vkuwrcxTADdU4rgvGsMXC7RulwYImDcJSiUn9a6kHIoRBTXl7jNUX37z2-Gx-xAye9Pp24rDRfLqXIO9UFx4=" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a> or <a href="https://www.globenewswire.com/Tracker?data=AaVGeP7K_EpAm5_xIEUEwEQ8dGZJ9NGS_P_MzP4ITATESpE8olbFAiZELSuApmMT8Uq4ZuZHxFk6EtewwCZy6Xk-zh0RJS9G9UUK3t-TGjJbyMomY-TTquef0M44Jz1S" rel="nofollow" target="_blank">fjohnson@johnsonfistel.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc2MTEyNiM3NzAxMjE2IzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/M2E2ZWFhZDEtN2QxOC00MjBmLWE5ZWYtZDNmN2RiZGUxYTg3LTExOTMzNTgtMjAyNi0wNy0xMy1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

Johnson Fistel is investigating Treace Medical Concepts (TMCI) for potential fiduciary-duty breaches. The release highlights possible governance reforms and shareholder remedies for long-term holders, tied to allegations about Lapiplasty demand and revenue declines. The catalyst is ongoing legal scrutiny, with limited immediate cash impact and potential sentiment risk if new facts emerge.

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI)

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News